Consilium MedicumConsilium MedicumConsilium MedicumConsilium Medicum2075-17532542-2170Consilium Medicum9509210.26442/2075-1753_2018.10.65-71ArticlesСтатьиReview ArticleFixed combination of perindopril and bisoprolol in cardiovascular disease treatmentМесто фиксированной комбинации периндоприла и бисопролола в лечении сердечно-сосудистых заболеванийBaryshnikovaG. AБарышниковаГалина Анатольевна

д-р мед. наук, проф. каф. семейной медицины с курсами клинической лабораторной диагностики, психиатрии и психотерапии

bargalan@mail.ruChorbinskayaS. AЧорбинскаяСветлана Алексеевна

д-р мед. наук, проф., зав. каф. семейной медицины с курсами клинической лабораторной диагностики, психиатрии и психотерапии

StepanovaI. IСтепановаИрина Ираклиевна

канд. мед. наук, доц. каф. семейной медицины с курсами клинической лабораторной диагностики, психиатрии и психотерапии

BlohinaO. EБлохинаОльга Евгеньевна

ассистент каф. семейной медицины с курсами клинической лабораторной диагностики, психиатрии и психотерапии

Central State Medical Academy of the President of the Russian FederationФГБУ ДПО ЦГМА УД Президента РФ151020182010VOL 20, NO10 (2018)ТОМ 20, №10 (2018)657128122021Copyright ©; 2018, Consilium MedicumCopyright ©; 2018, ООО "Консилиум Медикум"2018Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc-sa/4.0https://consilium.orscience.ru/2075-1753/article/view/95092

The review presents information on fixed combination of b-adrenoblocker bisoprolol and angiotensin-converting enzyme inhibitor perindopril. Advantages of each drug included in Prestilol, its mechanism of action, organo-protective effect and prognosis influence are reviewed in detail. Also we discuss clinical cases where use of such fixed combination is more optimal and effective.

В обзоре предоставлена информация о фиксированной комбинации b-адреноблокатора бисопролола и ингибитора ангиотензинпревращающего фермента периндоприла. Подробно рассмотрены достоинства каждого из препаратов, вошедших в препарат Престилол, механизм действия, органопротективные эффекты и влияние на прогноз. Рассмотрены также клинические ситуации, в которых использование подобной фиксированной комбинации окажется наиболее оптимальным и эффективным.

arterial hypertensioncombined antihypertensive therapyfixed combinationbisoprololperindoprilPrestilolартериальная гипертензиякомбинированная антигипертензивная терапияфиксированная комбинациябисопрололпериндоприлПрестилолGlobal Burden of Disease Study 2013 Collaborators. Lancet 2015; 386 (9995): 743-800.Law M.R, Wald N.J, Morris .JK, Jordan R.E. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003; 326: 1427-35.Wald D.S, Law M, Morris J.K et al. Combination therapy vs. monotherapy in reducing blood pressure: meta-analysis on 11 000 participants from 42 trials. Am J Med 2009; 122: 290-300.Gradman A.H, Basile J.N, Carter B.L, Bakris G.L. American Society of Hypertension Writing Group (2010) Combination therapy in hypertension. J Am Soc Hypertens 2010; 4: 42-50.Liou Y.S, Ma T, Tien L et al. The relationship between antihypertensive combination therapies comprising diuretics and/or beta-blockers and the risk of new-onset diabetes: a retrospective longitudinal cohort study. Hypertens Res 2009; 32 (6): 496-9.2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31 (7): 1281-357.Fung V, Huang J, Brand R. Hypertension treatment in a medicare population: adherence and systolic blood pressure control. Clin Ther 2007; 29: 972-84.Bangalore S, Kamalakkannan G, Parkar S, Messerli F.H. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007; 120: 713-9.Weber M.A, Schiffrin E.L, White W.B et al. Clinical Practice Guidelines for Management of Hyperyension in the Community. О Clin Hypertension 2014; 16 (1): 14-26.Egan B.M, Bandyopadhyay D, Shaftman S.R et al. Initial monotherapy and combination therapy and hypertension control the first year. Hypertension 2012; 59 (6): 1124-31.Thorin E, Thorin-Trescases N. Vascular endothelial ageing, heartbeat after heartbeat. Cardiovasc Res 2009; 84 (1): 24-32.Degaute J.P, Leeman M, Desert P. Long-term acceptability of perindopril: European multicenter trial on 856 patients. Am J Med 1992; 92 (Suppl. 4B): 84-90.Speirs C, Wagniart F, Poggi L. Perindopril postmarketing surveillance: a 12 month study in 47 351 hypertensive patients. Brit J Clin Pharmacol 1998; 46: 63-70.Myers M.G. A dose-response study of perindopril in hypertension: effects on blood pressure 6 and 24 h after dosing. Can J Cardiology 1996; 12: 1191-6.Tsoukas G, Anand S, Yang K. CONFIDENCE Investigators. Dose-dependent antihypertensive efficacy and tolerability of perindopril in a large, observational, 12-week, general practice-based study. Am J Cardiovasc Drug 2011; 11 (1): 45-55.London G.M, Pannier B, Guerin A.P et al. Cardiac hypertrophy aortic compliance, peripheral resistance, and wave reflection in end-stage renal disease. Comparative effects of ACE inhibition and calcium channel blockade. Circulation 1994; 90: 2786-96.Yalcin F, Aksoy F.G, Muderrisoglu H et al. Treatment of hypertension with perindopril reduces plasma atrial natriuretic peptide levels, left ventricular mass, and improves echocardiographic parameters of diastolic function. Clin Cardiol 2000; 23: 437-41.Asmar R, Topouchian J, Crisan O et al. Reversion of arterial abnormalities by long-term antihypertensive therapy in large population. The Compilor study. Eur Heart J 2000; 21 (Suppl.): 2366.Ghiadoni L, Huang Y, Magagna A et al. Effect of antihypertensive therapy on flow-mediated dilation in the brachial artery of essential hypertensive patients. High Blood Pressure 2000; 9 (Suppl.): 123.Fogari R, Mugellini A, Zoppi A. Effect of losartan and perindopril on plasma PAI-1 and fibrinogen in hypertensive type 2 diabetic patients. J Hypertens 1999; 17 (Suppl. 3): 58.Okrucka A, Pechan J, Kratochvilova H. Effects of the angiotensin-converting enzyme (ACE) inhibitor perindopril on endothelial and platelet function in essential hypertension. Platelets 1998; 9: 63-7.Fox K.M. European trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investiga-tors. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362 (9386): 782-8.Ceconi C, Francolini G, Olivares A et al. Angiotensin-converting enzyme (ACE) inhibitors have different selectivity for bradykinin binding sites of human somatic ACE. Eur J Pharmacol 2007; 577 (1-3): 1-6.Cleland J.G.F, Cohen-Solal A, Cosin Aguilar J et al. and the Study Group on Diagnostic of the Working Group on Heart Failure of the European Society of Cardiology. Management of heart failure in primary care (the IMPROVEMENT of Heart Failure Programme): an international survey. Lancet 2002; 23 (360): 1631-9.Vitovec J, Spinar J. First-dose hypotension after angiotensin-converting enzyme (ACE) inhibitors in chronic heart failure: a comparison of enalapril and perindopril. Eur J Heart Fail 2000; 2: 299-304.Cleland J.G, Tendera M, Adamus J et al. Perindopril for elderly people with chronic heart failure: the PEP-CHF study. The PEP investigators. Eur J Heart Fail 1999; 1: 211-7.Cleland J.G, Tendera M, Adamus J et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 2006; 27: 2338-45.Brichard S.M, Santoni J.P, Thomas J.R et al. Long-term reduction of microalbuminuria after 1 year of angio-tensin-converting enzyme inhibition by perindopril in hypertensive insulin-treated diabetic patients. Diabet Metab 1989; 16: 30-6.Hermans M.P, Brichard S.M, Colin I et al. Long-term reduction of microalbuminuria afteryears of angiotensin-converting enzyme inhibition by perindopril in hypertensive insulin-treated diabetic patients. Am J Med 1992; 92 (Suppl. 4B): 102-7.Campbell D.J. A Review of Perindopril in the Reduction of Cardiovascular Events. J Vasc Health Risk Manag 2006; 2 (2): 117-24.Di Nicolantonio J.J, O'Keefe Vasc J.H. Perindopril for improving cardiovascular events. Health Risk Manag 2014; 10: 539-48.Smith C, Teitler M. Beta-blocker selectivity at cloned human beta 1- and beta 2-adrenergic receptors. Cardiovasc Drugs Ther 1999; 13 (2): 123-6.Nuttall S.L, Routledge H.C, Kendall M.J. A comparison of the beta1-selectivity of three beta1-selective beta-blockers. J Clin Pharm Ther 2003; 28 (3): 179-86.Prichard B, Cruickshank J, Graham B. Beta-adrenergic blocking drugs in the treatment of hypertension. Blood Pressure 2001; 10: 366-86.Channaraya V, Marya R.K, Somasundaram M et al. Efficacy and tolerability of a β-1 selective β blocker, bisoprolol, as a first-line antihypertensive in Indian patients diagnosed with with essential hypertension (BRIGHT): an open-label, multicentric observational study. BMJ Open 2012; 2: e000683. DOI: 10.1136/bmjopen-2011-000683.De la Sierra A, Gorostidi M, Banegas J.R et al. Ambulatory Blood Pressures in Hypertensive Patients Treated With One Antihypertensive Agent: Differences Among Drug. 2015; 17 (11): 857-65.Zhou W.J, Wang R.Y, Li Y et al. A Randomized Controlled Study on the Effects of Bisoprolol and Atenolol on Sympathetic Nervous Activity and Central Aortic Pressure in Patients with Essential Hypertension. PLoS ONE 2013; 8 (9): e72102.Neutel J, Smith D, Rum C et al. Comparison of bisoprolol with atenolol for systemic hypertension in four population groups (young, old, black and non black) using ambulatory blood pressure monitoring. Bisoprolol Investigators Group. Am J Cardiol 1993; 72 (1): 41-6.Chatterjee S.S. The cardioselective and hypotensive effects of bisoprolol in hypertensive asthmatics. J Cardiovasc Pharmacol 1986; 8 (Suppl. 11): 74-7.Janka H.U, Ziegler A.G, Disselhoff G et al. Influence of bisoprolol on blood glucose, glucosuria, and haemoglobin A1 in noninsulin-dependent diabetics. J Cardiovasc Pharmacol 1986; 8 (Suppl 11): S96-S99.Fogari R, Zoppi A, Pasotti C et al. Effects of different beta-blockers on lipid metabolism in chronic therapy of hypertension. Int J Clin Pharmacol Ther Toxicol 1988; 26 (12): 597-604.Haneda T, Ido A, Fujikane T et al. Effect of bisoprolol, a beta 1-selective beta-blocker, on lipid and glucose metabolism and quality of life in elderly patients with essential hypertension. Nippon Ronen Igakkai Zasshi 1998; 35 (1): 33-8.Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectiveveli-disigned overviews of randomized trials. Lancet 2003; 362: 1527-35.Boissel J.P, Collet J.P, Lion L et al. A randomized comparison of the effect of four antihypertensive monotherapies on the subjective quality of life in previously untreated asymptomatic patients: field trial in general practice. The OCAPI Study Group. Optimiser le Choix d’un Anti-hypertenseur de Premiere Intention. J Hypertens 1995; 13 (9): 1059-6.Broncel M et al. 1998; Czuriga I, Riecansky I, Bodnar J et al. Comparison of the new cardioselective beta-blocker nebivolol with bisoprolol in hypertension: the Nebivolol, Bisoprolol Multicenter Study (NEBIS). Cardiovasc Drug Ther 2003; 17 (3): 257-63.Czuriga I, Riecansky I, Bodnar J et al. Comparison of the new cardioselective beta-blocker nebivolol with bisoprolol in hypertension: the Nebivolol, Bisoprolol Multicenter Study (NEBIS). Cardiovasc Drug Ther 2003; 17 (3): 257-63.CIBIS Investigators and Committees: Lechat Ph et al. A randomized trial of b-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 1994; 90: 1765.CIBIS II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS II): a randomized trial. Lancet 1999; 353: 9.WHO Model List of Essential Medicines. April 2015. 19th edition.De Champlain J, Karas M, Toal C et al. Effects of antihypertensive therapies on the sympathetic nervous system. Can J Cardiol 1999; 15: 8A-14A.Madej A, Buldak L, Basiak M et al. The effects of 1 month antihypertensive treatment with perindopril, bisoprolol or both on the ex vivo ability of monocytes to secrete inflammatory cytokines. J Clin Pharmacol Iher 2009; 47 (11): 686-94.Thoenes M, Neuberger H.R, Volpe M et al. Antihypertensive drug therapy and blood pressure control in men and women: an international perspective. J Hum Hypertens 2010; 24 (5): 336-44.Law M.R, Morris J.K, Wald N.J. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338: b1665.Raposeiras-Roubin S, Abu-Assi E, Redondo-Dieguez A et al. Prognostic benefit of beta-blockers after acute coronary syndrome with preserved systolic function. Still relevant today? Esp Cardiol 2015; 68 (7): 585-91.Zhang H, Yuan X, Zhang H et al. Efficacy of Long-Term P-Blocker Therapy for Secondary Prevention ofLong-Term Outcomes After Coronary Artery Bypass Grafting Surgery. Circulation 2015; 131 (25): 2194-201.Gradman A.H et al. Combination therapy in hypertension. J Clin Hypertens 2011; 13: 146-54.Bertrand M.E, Ferrari R, Remme W.J et al. Perindopril and b-blocker for the prevention of cardiac events and mortality in stable coronary artery disease patients: A European trial on Reduction Of cardiac events with Perindopril in stable coronary Artery disease (EUROPA) subanalysis. Am Heart J 2015; 170: 1092-8.Magrini G, Nicolosi G.L, Chiariello M et al. Rationale, characteristics and study design of PREAMI (Perindopril and Remodelling in the Elderly with Acute Myocardial Infraction. Ital Heart J 2005; 6 (Suppl. 7): 14S-23S.Lechat P, Brunhuber K.W, Hofmann R et al. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999; 35 (9146): 9-13.Brugts J.J, Bertrand M, Remme W et al. The Treatment Effect of an ACE-Inhibitor Based Regimen with Perindopril in Relation to Beta-Blocker use in 29,463 Patients with Vascular Disease: a Combined Analysis of Individual Data of ADVANCE, EUROPA and PROGRESS Trials. Cardiovasc Drug Ther 2017; 31 (4): 391-400.Kannel W.B, Wolf P.A, Benjamin E.J, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Аm J Cardiol 1998; 82 (8A): 2N-9N.Lewington S, Clarke R, Qizilbash N et al. Prospective Studies Collaboration. Agespecific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903-13.Antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with hypertension-2 study. Lancet 1999; 354 (9192): 1751-6.Dahlof B, Devereux R.B, Kjeldsen S.E еt al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002; 359 (9311): 995-1003.